Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 11.92
ALXN's Cash to Debt is ranked higher than
68% of the 1430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. ALXN: 11.92 )
ALXN' s 10-Year Cash to Debt Range
Min: 0.54   Max: No Debt
Current: 11.92

Equity to Asset 0.79
ALXN's Equity to Asset is ranked higher than
82% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALXN: 0.79 )
ALXN' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.93
Current: 0.79

0.27
0.93
Interest Coverage 291.32
ALXN's Interest Coverage is ranked higher than
53% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 291.32 )
ALXN' s 10-Year Interest Coverage Range
Min: 14.38   Max: 9999.99
Current: 291.32

14.38
9999.99
F-Score: 8
Z-Score: 26.81
M-Score: -2.32
WACC vs ROIC
10.85%
48.69%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 38.89
ALXN's Operating margin (%) is ranked higher than
97% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -90.24 vs. ALXN: 38.89 )
ALXN' s 10-Year Operating margin (%) Range
Min: -10370.21   Max: 38.89
Current: 38.89

-10370.21
38.89
Net-margin (%) 29.41
ALXN's Net-margin (%) is ranked higher than
96% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. ALXN: 29.41 )
ALXN' s 10-Year Net-margin (%) Range
Min: -10220.86   Max: 76.31
Current: 29.41

-10220.86
76.31
ROE (%) 22.83
ALXN's ROE (%) is ranked higher than
96% of the 1309 Companies
in the Global Biotechnology industry.

( Industry Median: -30.42 vs. ALXN: 22.83 )
ALXN' s 10-Year ROE (%) Range
Min: -136.75   Max: 63.11
Current: 22.83

-136.75
63.11
ROA (%) 17.91
ALXN's ROA (%) is ranked higher than
97% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: -25.96 vs. ALXN: 17.91 )
ALXN' s 10-Year ROA (%) Range
Min: -45.22   Max: 46.71
Current: 17.91

-45.22
46.71
ROC (Joel Greenblatt) (%) 151.50
ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -335.68 vs. ALXN: 151.50 )
ALXN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -963.15   Max: 172.59
Current: 151.5

-963.15
172.59
Revenue Growth (3Y)(%) 39.50
ALXN's Revenue Growth (3Y)(%) is ranked higher than
95% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. ALXN: 39.50 )
ALXN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -70.5   Max: 498.1
Current: 39.5

-70.5
498.1
EBITDA Growth (3Y)(%) 52.40
ALXN's EBITDA Growth (3Y)(%) is ranked higher than
96% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ALXN: 52.40 )
ALXN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.1   Max: 72.8
Current: 52.4

-10.1
72.8
EPS Growth (3Y)(%) 53.00
ALXN's EPS Growth (3Y)(%) is ranked higher than
96% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. ALXN: 53.00 )
ALXN' s 10-Year EPS Growth (3Y)(%) Range
Min: -15.3   Max: 77.3
Current: 53

-15.3
77.3
» ALXN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ALXN Guru Trades in Q1 2014

Paul Tudor Jones 5,725 sh (New)
Ray Dalio 50,371 sh (New)
Joel Greenblatt 5,026 sh (New)
Ron Baron 10,218 sh (New)
John Burbank 1,318 sh (New)
Pioneer Investments 31,453 sh (+3.12%)
Frank Sands 5,268,418 sh (-28.52%)
Steven Cohen 45,697 sh (-32.34%)
Andreas Halvorsen 1,836,658 sh (-36.16%)
» More
Q2 2014

ALXN Guru Trades in Q2 2014

Jim Simons 245,552 sh (New)
Joel Greenblatt 17,094 sh (+240.11%)
Andreas Halvorsen 2,006,092 sh (+9.23%)
Pioneer Investments 31,934 sh (+1.53%)
Frank Sands 5,279,782 sh (+0.22%)
Steven Cohen 11,700 sh (unchged)
John Burbank Sold Out
Ron Baron 10,145 sh (-0.71%)
Ray Dalio 26,332 sh (-47.72%)
Paul Tudor Jones 1,326 sh (-76.84%)
» More
Q3 2014

ALXN Guru Trades in Q3 2014

Paul Tudor Jones 3,120 sh (+135.29%)
Ron Baron 12,941 sh (+27.56%)
Andreas Halvorsen 2,198,451 sh (+9.59%)
Frank Sands 5,311,488 sh (+0.60%)
Pioneer Investments 30,500 sh (unchged)
Ray Dalio Sold Out
Steven Cohen Sold Out
Jim Simons 206,152 sh (-16.05%)
Joel Greenblatt 1,804 sh (-89.45%)
» More
Q4 2014

ALXN Guru Trades in Q4 2014

Ray Dalio 18,513 sh (New)
Joel Greenblatt 85,974 sh (+4665.74%)
Ron Baron 18,366 sh (+41.92%)
Pioneer Investments 30,795 sh (+0.97%)
Frank Sands 5,267,903 sh (-0.82%)
Frank Sands 5,267,903 sh (-0.82%)
Jim Simons 152,552 sh (-26.00%)
Paul Tudor Jones 1,487 sh (-52.34%)
Andreas Halvorsen 390,271 sh (-82.25%)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Alexion Pharmaceuticals Inc

Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Alexion Pharmaceuticals Inc, Equity Residential, and Tableau Software Inc. Read more...
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY
According to GuruFocus Insider Data, the largest insider sells during the past week were: Oracle Corporation (ORCL), Alexion Pharmaceuticals Inc (ALXN), Waters Corp (WAT) and DENTSPLY International Inc (XRAY). Read more...
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock
The CEO of Alexion Pharmaceuticals Inc (ALXN), Leonard Bell, sold more than 100,000 shares of company stock Wednesday for nearly $17 million. At a price of $160.71 per share, the sale of 105,000 shares of company stock brought $16,874,551. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 55.50
ALXN's P/E(ttm) is ranked higher than
90% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 55.50 )
ALXN' s 10-Year P/E(ttm) Range
Min: 13.92   Max: 1113.68
Current: 55.5

13.92
1113.68
Forward P/E 25.71
ALXN's Forward P/E is ranked higher than
89% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 25.71 )
N/A
PE(NRI) 56.10
ALXN's PE(NRI) is ranked higher than
92% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 56.10 )
ALXN' s 10-Year PE(NRI) Range
Min: 13.96   Max: 1058
Current: 56.1

13.96
1058
P/B 10.90
ALXN's P/B is ranked lower than
51% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 6.80 vs. ALXN: 10.90 )
ALXN' s 10-Year P/B Range
Min: 1.73   Max: 162.14
Current: 10.9

1.73
162.14
P/S 16.37
ALXN's P/S is ranked higher than
64% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 37.92 vs. ALXN: 16.37 )
ALXN' s 10-Year P/S Range
Min: 9.66   Max: 1115.3
Current: 16.37

9.66
1115.3
PFCF 72.90
ALXN's PFCF is ranked higher than
91% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 72.90 )
ALXN' s 10-Year PFCF Range
Min: 40   Max: 99999999.99
Current: 72.9

40
99999999.99
POCF 57.52
ALXN's POCF is ranked higher than
92% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 57.52 )
ALXN' s 10-Year POCF Range
Min: 33.16   Max: 83.87
Current: 57.52

33.16
83.87
EV-to-EBIT 38.31
ALXN's EV-to-EBIT is ranked higher than
93% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 38.31 )
ALXN' s 10-Year EV-to-EBIT Range
Min: -98.6   Max: 893.9
Current: 38.31

-98.6
893.9
PEG 1.07
ALXN's PEG is ranked higher than
99% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 1.07 )
ALXN' s 10-Year PEG Range
Min: 0.68   Max: 2.63
Current: 1.07

0.68
2.63
Shiller P/E 119.60
ALXN's Shiller P/E is ranked higher than
92% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 119.60 )
ALXN' s 10-Year Shiller P/E Range
Min: 98.32   Max: 655.33
Current: 119.6

98.32
655.33
Current Ratio 4.61
ALXN's Current Ratio is ranked higher than
73% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. ALXN: 4.61 )
ALXN' s 10-Year Current Ratio Range
Min: 3.28   Max: 45.4
Current: 4.61

3.28
45.4
Quick Ratio 4.32
ALXN's Quick Ratio is ranked higher than
73% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. ALXN: 4.32 )
ALXN' s 10-Year Quick Ratio Range
Min: 2.69   Max: 45.4
Current: 4.32

2.69
45.4
Days Inventory 289.75
ALXN's Days Inventory is ranked higher than
79% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 289.75 )
ALXN' s 10-Year Days Inventory Range
Min: 202.61   Max: 959.95
Current: 289.75

202.61
959.95
Days Sales Outstanding 70.74
ALXN's Days Sales Outstanding is ranked higher than
80% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 128.03 vs. ALXN: 70.74 )
ALXN' s 10-Year Days Sales Outstanding Range
Min: 70.74   Max: 451.45
Current: 70.74

70.74
451.45

Valuation & Return

vs
industry
vs
history
Price/Net Cash 33.90
ALXN's Price/Net Cash is ranked higher than
59% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 105.00 vs. ALXN: 33.90 )
ALXN' s 10-Year Price/Net Cash Range
Min: 1.68   Max: 168.3
Current: 33.9

1.68
168.3
Price/Net Current Asset Value 24.40
ALXN's Price/Net Current Asset Value is ranked higher than
61% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. ALXN: 24.40 )
ALXN' s 10-Year Price/Net Current Asset Value Range
Min: 1.62   Max: 60.32
Current: 24.4

1.62
60.32
Price/Tangible Book 14.60
ALXN's Price/Tangible Book is ranked higher than
50% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 9.90 vs. ALXN: 14.60 )
ALXN' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 34.74
Current: 14.6

1.5
34.74
Price/DCF (Projected) 5.10
ALXN's Price/DCF (Projected) is ranked higher than
92% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 5.10 )
ALXN' s 10-Year Price/DCF (Projected) Range
Min: 4.34   Max: 26.5
Current: 5.1

4.34
26.5
Price/Median PS Value 0.90
ALXN's Price/Median PS Value is ranked higher than
89% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 3.04 vs. ALXN: 0.90 )
ALXN' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 56.1
Current: 0.9

0.37
56.1
Price/Peter Lynch Fair Value 2.20
ALXN's Price/Peter Lynch Fair Value is ranked higher than
97% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 2.20 )
ALXN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56   Max: 4.22
Current: 2.2

0.56
4.22
Price/Graham Number 6.00
ALXN's Price/Graham Number is ranked higher than
90% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 6.00 )
ALXN' s 10-Year Price/Graham Number Range
Min: 2.11   Max: 8.91
Current: 6

2.11
8.91
Earnings Yield (Greenblatt) 2.60
ALXN's Earnings Yield (Greenblatt) is ranked higher than
90% of the 1388 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. ALXN: 2.60 )
ALXN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3
Current: 2.6

0.1
3
Forward Rate of Return (Yacktman) 52.86
ALXN's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 15.79 vs. ALXN: 52.86 )
ALXN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -18.5   Max: 75.6
Current: 52.86

-18.5
75.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AXP.Germany, 0QZM.UK,
Alexion Pharmaceuticals Inc is a Delaware based company, incorporated in 1992. The Company is a biopharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company is also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. It operates in United States, Europe and Asia Pacific. It competes with companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and in other countries and regions, as well as a growing number of large pharmaceutical companies that are developing biotechnology products. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of products and product candidates, including Soliris, are subject to extensive regulation by governmental authorities in the United States, the European Union and other territories.
» More Articles for ALXN

Headlines

Articles On GuruFocus.com
Alexion Pharma Downgraded Despite Progress in Pipeline Jan 05 2015 
Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 10 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Six High-Impact Sells - Viking Global Investors Aug 27 2013 
CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 


More From Other Websites
The Zacks Analyst Blog Highlights: Medicines Co., Tekmira, GW Pharmaceuticals, Biogen and Alexion -... Apr 16 2015
Former Teva CEO's new gig at Ovid Therapeutics Apr 16 2015
Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog Apr 13 2015
Alexion Announces Presentations at 2015 American Transplant Congress, Including Results from Studies... Apr 13 2015
Alexion Receives Approval for Important Updates to the European Label for Soliris® (eculizumab) Apr 10 2015
Alexion Pharmaceuticals to Report First Quarter 2015 Results on Thursday, April 23, 2015 Apr 09 2015
Alexion Pharmaceuticals to Report First Quarter 2015 Results on Thursday, April 23, 2015 Apr 09 2015
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Apr 07 2015
These 10 Pharma and Health Care Stocks Were the Worst S&P 500 Performers Last Quarter Apr 02 2015
Economic Indicators Move Equities and Bonds Apr 01 2015
3 Top-Rated Biotechs Could Take Buy Points Soon Mar 31 2015
Why Citigroup Removed Gilead Sciences From Its 'Most Preferred' List Mar 30 2015
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 26 2015
One analyst is convinced the biotech stock plunge is 'misguided' Mar 26 2015
Two Healthcare Stocks Provide Antidotes To Wild Market Swings Mar 24 2015
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 16 2015
Affymetrix Hits 52-Week High on Stellar Q4, Positive Outlook - Analyst Blog Mar 13 2015
Analyst: Alexion Pharmaceuticals Pipeline Is Undervalued Mar 11 2015
New Data from First Natural History Study in Juveniles with Hypophosphatasia (HPP) Showing... Mar 07 2015
FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia Mar 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK